Autor: Papuc, E. - Katalog OPAC zbiorów

Skocz do pozycji: 1.

Tytuł:: Humoral response against myelin associated glycoprotein reflects oligodendroglial degeneration in Parkinson’s disease
Autorzy:: Papuc, E.
Wilczynska, B.
Rejdak, K.
Powiązania:: https://bibliotekanauki.pl/articles/51200.pdf
Data publikacji:: 2016
Wydawca:: Instytut Medycyny Wsi
Źródło:: Annals of Agricultural and Environmental Medicine; 2016, 23, 2
1232-1966
Pojawia się w:: Annals of Agricultural and Environmental Medicine
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Skocz do pozycji: 2.

Tytuł:: Continuous subcutaneous apomorphine monotherapy in Parkinson’s disease
Autorzy:: Papuć, E.
Trzciniecka, O.
Rejdak, K.
Powiązania:: https://bibliotekanauki.pl/articles/2082065.pdf
Data publikacji:: 2018
Wydawca:: Instytut Medycyny Wsi
Tematy:: Parkinson’s disease
apomorphine
continuous subcutaneous infusion
monotherapy
apomorphine pump
Opis:: Introduction and objective. Continuous subcutaneous apomorphine (APO) treatment is one of the 3 therapeutic options for advanced Parkinson’s disease (PD), in addition to deep brain stimulation (DBS) and intrajejunal levodopa. Data from previously performed studies show that few PD patients can achieve APO infusion as monotherapy. The current pilot study presents the authors’ experience in achieving APO monotherapy. Materials and method. During the last 2 years, 9 patients with APO were treated in the Department of Neurology of the Medical University of Lublin; each patient was offered a 5-day duration APO treatment as monotherapy. The main indication for the APO therapy was advanced PD with motor fluctuations and the patient’s non-agreement for DBS therapy. Mean age of treated patients – 65.11 years, mean disease duration – 7.67 years, mean Hoehn-Yahr – 2.67, mean L-dopa equivalent before APO treatment – 1751.11 mg, mean daily dose of apomorphine as monotherapy – 106.11 ± 14.09 mg. Results. All treated patients managed to achieve APO monotherapy. A statistically significant reduction was found in the duration of the ‘off’ states in the observed PD patients on APO monotherapy (p<0.05). No significant improvement was observed in the III motor score of the UPDRS on APO treatment, compared to optimized oral therapy used before APO treatment. Conclusions. APO monotherapy can be achieved in advanced PD, and seems to be a good therapeutic option for this group of patients, especially in that it allows a significant reduction in the off-time which significantly simplifies the drug regime. Nevertheless, hospital admission with experienced neurologist supervision is recommended when establishing a PD patient’s APO monotherapy.
Źródło:: Annals of Agricultural and Environmental Medicine; 2019, 26, 1; 133-137
1232-1966
Pojawia się w:: Annals of Agricultural and Environmental Medicine
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Informacja

Wyszukujesz frazę "Papuc, E." wg kryterium: Autor

Źródło danych

Dostawca treści

Kolekcja

Rok wydania

Wydawca

Temat

Autor

Typ dokumentu

Język